Laboratory Biosafety Manual, Fourth Edition
The de facto global reference for laboratory biosafety. The fourth edition moves decisively from prescriptive containment levels to a risk- and evidence-based approach, in which facilities, equipment and work practices are chosen proportionate to an assessed risk rather than assigned by category.
What this does not cover
stated in the document's own scope- It is guidance; binding requirements come from national biosafety and occupational health law.
- It addresses biosafety and biosecurity in laboratories, not the quality of laboratory results.
- It protects laboratory workers and the community; it does not address the regulatory status of the tests or products the laboratory handles.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The WHO Laboratory biosafety manual, fourth edition, known as LBM4, is the reference WHO describes as a de facto global standard for biosafety in clinical and public health laboratories and other biomedical settings. It builds on the risk assessment framework introduced in the third edition and moves to an evidence- and risk-based approach, in which safety measures are balanced with the actual risk of the work on a case-by-case basis. WHO announced its publication on 14 January 2021, and it consists of a core document and seven subject-specific monographs.
Scope & applicability
Work with biological agents in laboratory and related settings, supported by seven subject-specific monographs. Its shift away from fixed requirements is the important one for regulated manufacture: containment is argued from a documented risk assessment rather than inherited from a biosafety-level label, which is the same reasoning GMP applies to contamination control.
Legal basis & how it acquires force
A WHO guidance publication. It has no legal force of its own: countries use it to develop national codes of practice and regulations for the safe handling of biological agents, and laboratories adopt it directly. WHO states that LBM has encouraged countries to accept basic biological safety concepts and to develop national codes of practice for the safe handling of biological agents in laboratories.
Document structure
| Part | Covers |
|---|---|
| Core document | The risk assessment framework and the selection of risk control measures, biosafety programme management and laboratory biosecurity |
| Core requirements | The minimum set of requirements for safe work with biological agents, applicable to most laboratory work |
| Heightened control measures | Additional risk control measures where the risk assessment shows a higher risk |
| Maximum containment measures | Highly detailed and stringent measures for the highest-risk work |
| Monographs | Seven subject-specific monographs, including risk assessment, personal protective equipment and biosafety programme management |
Key requirements
- Risk assessment as the basis for control selection, replacing prescriptive assignment by containment level
- Core requirements applicable to all laboratories, with heightened and maximum containment measures added on assessed risk
- Good microbiological practice and procedure as the foundation regardless of containment level
- Personnel competence, decontamination and waste management, and incident response
- Seven associated monographs covering risk assessment, biosafety programme management and related topics
Implementation tips
- Containment and cleanroom design pull in opposite directions — negative pressure to protect people and environment, positive pressure to protect product — and a facility doing both has to resolve that by design rather than by procedure
- The risk-based framing means the assessment is the deliverable: a containment decision inherited from a biosafety-level label, with no documented assessment behind it, is exactly what the fourth edition moved away from
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
LBM4 replaces the earlier approach of assigning work to fixed containment levels by risk group with control measures selected from an assessed risk. It is used alongside national biosafety regulations and, for laboratories that also work under GxP, alongside GLP, GMP or clinical laboratory requirements, which address data and product quality rather than worker and community protection.
WHO LBM 4th ed. (2020): frequently asked questions
Quick answers to common questions about WHO LBM 4th ed. (2020).
What is the main change in the fourth edition?
It builds on the third edition’s risk assessment framework with an evidence- and risk-based approach, so safety measures are balanced with the actual risk of the work on a case-by-case basis rather than assigned by category.
What does LBM4 consist of?
A core document and seven subject-specific monographs, according to WHO.
What are core requirements?
A set of minimum requirements defined in LBM4 for safe work with biological agents, with heightened control measures and maximum containment measures added where the assessed risk requires them.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.